Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.53 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7082918 | 0.91 | CCR2 (0.55) | CCR2NOD2NOD1MAPTHTT | |
| SCHEMBL7083180 | 0.90 | ABCB11 (0.52) | CCR2NOD2NOD1MAPTHTT | |
| SCHEMBL7596035 | 0.88 | NOD2 (0.53) | CCR2NOD2NOD1MAPTHTT | |
| SCHEMBL6307761 | 0.86 | NOD2 (0.60) | CCR2NOD2NOD1MAPTHTT | |
| SCHEMBL6300605 | 0.83 | CCR2 (0.72) | CCR2NOD2NOD1MAPTHTT | |
| SCHEMBL7594730 | 0.82 | NOD2 (0.56) | CCR2NOD2NOD1MAPTHTT | |
| SCHEMBL7088272 | 0.82 | NOD2 (0.47) | CCR2NOD2NOD1MAPTHTT | |
| SCHEMBL7086760 | 0.82 | ABCB11 (0.53) | CCR2NOD2NOD1MAPTHTT | |
| SCHEMBL6300934 | 0.81 | NOD2 (0.66) | CCR2NOD2NOD1MAPTHTT | |
| SCHEMBL6300560 | 0.80 | NOD2 (0.58) | CCR2NOD2NOD1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| EP-1252142-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001051466-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | CCR2, CCR1, CCR5 | CCR2 1/4885NOD2 651/4885NOD1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.